Evidence map›Paper›PMID 38706606›Full record

ArticleFrontiers in oncology2024

Case report: Immunotherapy inducing unexpected overall survival in choroidal melanoma: about a case.

Youssef Elhaitmy, Soukaina El Anssari, Pierre Fournel, Nawfel Mellas, Wafa Bouleftour, Michele Lamuraglia

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Youssef ElhaitmyDepartment of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
Soukaina El AnssariDepartment of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
Pierre FournelDepartment of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
Nawfel MellasDepartment of Oncology, Hassan II University Hospital, Fez, Morocco.
Wafa BouleftourDepartment of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
Michele LamuragliaDepartment of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choroidal melanoma (CM) is the most common malignant ocular tumor in adults. The current treatment of metastatic CM is limited by the intrinsic resistance of CM to conventional systemic therapies. Immunotherapy alone or in association with cytotoxic treatment became a realist option treatment. Advancements in molecular biology have resulted in the identification of a number of promising prognostic and therapeutic targets. Herein, we report a rare case of 36-year-old patient with metastatic CM who presented a good long response to treatment with double immunotherapy reaching 3 years of overall survival, which has never been described in the literature.

Indexed as

case reportchoroidal melanomaenucleationhepatic metastasesimmunotherapy

Identifiers

PMID38706606
PMCPMC11066258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.